Fig. 3From: Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysisCost-effectiveness acceptability curve showing the probability that therapy including brentuximab vedotin is cost-effective at various levels of willingness-to-pay (WTP) per QALY gainedBack to article page